









Markets
/
Stocks
/
nasdaq-vktx
/

Viking Therapeutics Inc

VKTX

35.930USD

+1.510+4.39%

Close 10/27, 16:00（ET）Quotes delayed by 15 min

4.04BMarket Cap

LossP/E TTM



Viking Therapeutics Inc

35.930

+1.510+4.39%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Viking Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

The company's fundamentals are relatively very weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Viking Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

140 / 501

Overall Ranking

268 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 17 analysts

Buy

Current Rating

93.250

Target Price

+170.92%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Viking Therapeutics Inc Highlights

StrengthsRisks

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Overvalued

The company’s latest PE is -16.95, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 76.32M shares, decreasing 19.54% quarter-over-quarter.

Held by Stanley Druckenmiller

Star Investor Stanley Druckenmiller holds 549.29K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.13.

Financial Health

Currency: USD Updated: 2025-10-27

The company's current financial score is 3.80, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

3.80

Change



Financials

0.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.28

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

4.70

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Viking Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.94, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -16.95, which is -79.92% below the recent high of -3.40 and -512.39% above the recent low of -103.80.

Score

Industry at a Glance

Previous score

6.94

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 140/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 8.71, which is higher than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Viking Therapeutics Inc is 100.50, with a high of 125.00 and a low of 36.00.

Score

Industry at a Glance

Previous score

8.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 17 analysts

Buy

Current Rating

93.250

Target Price

+170.92%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

551

Total

Median

Average

Company name

Ratings

Analysts

Viking Therapeutics Inc

VKTX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 9.68, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 40.14 and the support level at 28.38, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.42

Change

0.26

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.206

Buy

RSI(14)

63.930

Neutral

STOCH(KDJ)(9,3,3)

66.795

Buy

ATR(14)

2.396

Low Volatility

CCI(14)

112.267

Buy

Williams %R

14.622

Overbought

TRIX(12,20)

1.003

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

33.734

Buy

MA10

33.886

Buy

MA20

32.437

Buy

MA50

28.746

Buy

MA100

29.927

Buy

MA200

29.257

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 67.87%, representing a quarter-over-quarter decrease of 5.68%. The largest institutional shareholder is The Vanguard, holding a total of 10.14M shares, representing 8.97% of shares outstanding, with 1.41% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

10.14M

-0.04%

Fidelity Management & Research Company LLC

7.63M

-25.41%

BlackRock Institutional Trust Company, N.A.

4.31M

-11.59%

State Street Investment Management (US)

3.78M

-6.90%

JP Morgan Asset Management

2.51M

-6.99%

Two Sigma Investments, LP

2.41M

+4488.87%

Fidelity Institutional Asset Management

2.19M

+114.64%

Susquehanna International Group, LLP

2.07M

+23.25%

Lian (Brian)

1.94M

+1.12%

Geode Capital Management, L.L.C.

1.92M

-3.08%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.60. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.